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Introduction: The aim of the study is to evaluate the current status
of treatment-related death (TRD) in lung cancer patients.
Methods: We retrospectively analyzed the incidence and risk fac-
tors of TRD in lung cancer patients who received chemotherapy
and/or thoracic radiotherapy using logistic regression analyses.
Results: Between January 2001 and December 2005, 1225 (222
small cell and 1003 non-small cell lung cancers) patients received
chemotherapy and/or thoracic radiotherapy as the initial treatment.
Of these, 43 patients receiving chemotherapy followed by thoracic
radiotherapy were included into both the chemotherapy-alone and
radiotherapy-alone groups. There were a total of 23 (1.9%) TRDs.
Chemotherapy-related deaths occurred in 7 of 927 (0.8%) patients,
including 4 from drug-induced lung injury, 2 from pneumonia, and
1 from unknown cause. Concurrent chemoradiotherapy-related deaths
occurred in 12 of 245 (4.9%) patients, including 11 from radiation
pneumonitis and 1 from pneumonia. Thoracic radiotherapy-related
deaths occurred in 4 of 96 (4.2%) patients. The incidence of chemo-
therapy-related death was correlated with poor performance status
(odds ratio [OR]: 11.4, 95% confidence interval [CI]: 3.53–37.1), the
presence of hypoxia (OR: 19.3, CI: 6.06–61.7), hyponatremia (OR:
45.5, CI: 13.4–154), and treatment with epidermal growth factor
receptor-tyrosine kinase inhibitors (OR: 8.56, CI: 2.48–29.5), whereas
the incidence of concurrent chemoradiotherapy-related death was cor-
related with pulmonary fibrosis (OR: 22.2, CI: 5.61–87.8). Radiother-
apy results were not analyzed because there were too few patients.
Conclusions: TRD occurred in 1.9% of the patients as a result of
treatment-related lung injury in the majority of the cases.
Key Words: Lung cancer, Treatment-related death, Risk factor,
Chemotherapy, Thoracic radiotherapy.
(J Thorac Oncol. 2012;7: 177–182)
Before any medical interventions are undertaken in patientswith lung cancer, they must be clearly informed about the
risks and benefits of the intervention(s) and about alternative
treatment options. Careful delivery of this is particularly impor-
tant if the planned treatment may not only result in cure but may
also be harmful. Provision of accurate information to help
patients make the most appropriate decision is therefore crucial.
However, the risks of death from drug toxicity and the inci-
dences of such events tend to be uncertain1–4 and also constantly
change with the wide use of newer agents, such as third-
generation chemotherapy agents, and molecular-targeted agents.
In addition, the incidence of treatment-related deaths (TRDs) has
not been thoroughly examined in clinical settings outside of
clinical trials. Prospective clinical trials for poor-risk patients are
often difficult to perform because of poor accrual, reflecting the
reluctance of physicians to subject patients with underlying comor-
bid illness to the toxic effects of chemotherapy and radiation.
Our ultimate goal is to prospectively identify individ-
uals who are at a high risk of TRD so as to provide the most
precise estimation of the possible risks to each patient. In this
study, we retrospectively examined the data of patients with
locally advanced or metastatic lung cancer who were treated
at the National Cancer Center Hospital, Tokyo, Japan, focus-
ing on the risks and incidences of TRD associated with
chemotherapy and radiotherapy.
PATIENTS AND METHODS
Patients
Between January 2001 and December 2005, a total of
1623 lung cancer patients were admitted to the thoracic
oncology ward at the National Cancer Center Hospital. All
patients were admitted in this period to be treated as part of
standard practice in Japan. Patients who received chemother-
apy alone usually stayed in the hospital for 7 to 10 days for
one cycle of chemotherapy, and those who received concur-
rent chemoradiotherapy stayed for 6 weeks. Among these, a
total of 1225 patients who had received first-line chemother-
apy and/or radiotherapy on an inpatient basis were extracted
from the institutional database. Additional details about the
patients, including the diagnostic imaging findings, were then
reviewed from the patients’ medical records. The data of
patients receiving chemotherapy and/or thoracic radiotherapy
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as the initial treatment were evaluated. They included patients
with stage III to IV disease and postoperative recurrent
disease who received chemotherapy; those with stage III
disease who received chemoradiotherapy or radiotherapy
alone; and those with stage III disease who received preop-
erative induction therapy or postoperative adjuvant therapy.
All the patients had been followed for at least 4 weeks after
the completion of treatment.
Treatment Selection
After a thorough evaluation of the operability and/or
curability, the eligibility of each patient for enrollment in an
open clinical trial was determined. Although patient recruit-
ment for protocol treatments is a priority of ours, patients
were free to refuse treatment. If no appropriate clinical trials
were scheduled or under way, the known best standard
treatments were administered.
Best Standard Treatments
For first-line treatment, patients with non-small cell
lung cancer (NSCLC) who were deemed inoperable but
curable with good local control with chemoradiotherapy re-
ceived three to four cycles of cisplatin (CDDP) 80 mg/m2 on
day 1  vinorelbine (VNR) 20 mg/m2 on days 1 and 8, every
4 weeks, along with early concurrent thoracic radiotherapy,
usually at a total dose of 60 Gy/30 fractions.5 Sequential
chemoradiotherapy, rather than concurrent chemoradiother-
apy, was offered if the calculated percentage of the total lung
volume receiving radiation in excess of 20 Gy (V20) was
more than 40%.6 Thoracic radiotherapy alone was selected if
chemotherapy could not be given due to comorbidity. If the
radiation field involved the contralateral hilum or if the
patients had malignant effusion and/or distant metastasis,
platinum doublet therapy was administered; the most com-
mon combination was four cycles of carboplatin (CBDCA)
area under the curve  6 on day 1  paclitaxel (PTX) 200
mg/m2 on day 1, every 3 weeks.7 For limited-disease SCLC,
four cycles of a combination of CDDP 80 mg/m2 on day 1 
etoposide 100 mg/m2 on days 1 to 3, every 4 weeks, were
administered concurrently with hyperfractionated thoracic
radiotherapy at a total radiation dose of 45 Gy in fractional
doses of 1.5 Gy, administered twice a day.8 In patients with
extensive-disease SCLC, four cycles of a combination of
CDDP 60 mg/m2 on day 1 and irinotecan (CPT) 60 mg/m2 on
days 1, 8, and 15, every 4 weeks, were usually administered.9
Radiotherapy was given using megavoltage photons (6–15
MV). The routine radiation schedule without chemotherapy
for locally advanced NSCLC was a total radiation dose of 60
to 66 Gy, or as high as 70 Gy, administered in fractional
doses of 2.0 Gy once a day.
Definition of TRD
Chemotherapy-related death was defined as death oc-
curring within 4 weeks of the completion of treatment,
without clear evidence of any other cause of death, or death
obviously caused by treatment toxicity. Radiotherapy-related
death was defined as death secondary to hypoxia or to
complications of corticosteroid administration after the diag-
nosis of radiation pneumonitis. Steroid therapy was adminis-
tered based on the attending physician’s discretion, without a
standardized treatment dose or duration, for the management
of radiation-induced lung injury.10
Definition of Treatment-Induced Lung Injury
The criteria of drug-induced lung injury in this study
were as follows: (1) appearance of new symptoms and radio-
logical abnormalities in the course of chemotherapy with the
onset within a few months of the start of the therapy; (2)
diffuse or multifocal ground-glass opacities and intralobular
interstitial thickening without segmental distribution in com-
puted tomography (CT) scans of the chest; and (3) no evi-
dence of underlying heart disease, infection, or lymphangitic
carcinomatosis. Lung biopsy was not routinely performed in
our hospital because patients were frequently too frail to
undergo biopsy. The criteria of radiation-induced lung injury
were (1) appearance of new symptoms and radiological
abnormalities with the onset within 6 months of the end of
thoracic radiotherapy; (2) opacification, diffuse haziness, in-
filtrates, or consolidation conforming to the outline of the
sharply demarcated irradiated area in CT scans; and (3) a
reduction in lung volume within the irradiated area and linear,
ground-glass opacities or reticular shadows beyond the irra-
diated area developing during clinical course. In contrast, the
criteria of bacterial pneumonia were (1) clinical suspicion of
pneumonia including rapidly developing fever and/or produc-
tive cough; and (2) consolidation spreading through anatom-
ical structure of the lung in CT scans.
Statistical Analysis
We investigated the associations between chemotherapy-
related or concurrent chemoradiotherapy-related death and the
potential risk factors at the time of diagnosis. The following
potential risk factors were investigated: sex, age (70 years
versus 70 years), performance status (Eastern Cooperative
Oncology Group criteria; 2–4 versus 0–1), smoking history
(presence versus absence), partial pressure of oxygen (70
mmHg  PO2 versus 70 mmHg), hemoglobin (Hgb  13.7
g/dl versus  13.7 g/dl), platelet (Plt  367  109/L versus
367  109/L), albumin (Alb  3.7 g/dl versus 3.7 g/dl),
sodium (Na 138mEq/L versus138mEq/L), clinical trial (in
versus out), and chemotherapy regimen (The cutoff values of
hemoglobin, platelet, albumin, and sodium are the institutional
normal limits [above or below]). For concurrent chemoradio-
therapy-related factors, the presence of coincidental diseases
such as emphysema (with versus without) or pulmonary fibrosis
(with versus without) and the location of the primary tumor
(lower lobe versus other lobes) were also included in the anal-
yses. The diagnostic criteria of pulmonary fibrosis were a linear,
ground-glass attenuation or reticular shadows on chest radio-
graphs and CT scans before treatment that were predominant in
the lower zone of the lung. Also, the influence of the chemo-
therapy regimens was evaluated.
In the univariate preliminary analysis, the relation be-
tween previously defined variables at the time of presentation
and the occurrence of the outcome variable (toxic death) was
assessed using the 2 test. To adjust for each factor, multi-
variate logistic regression analyses were planned. When the
number of observed events was less than 10, multivariate
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analysis was not performed. When the number of patients for
each factor was small, the factor was excluded from the
model, even when it appeared to be statistically significant.
All the analyses were performed using the STATISTICA 4.1J
program (StatSoft, Inc., Tulsa, OK).
RESULTS
Patient Characteristics
The patient characteristics before treatment are listed in
Table 1. Of the 1225 patients (SCLC: 222; adenocarcinoma:
652; squamous cell carcinoma: 194; NSCLC not otherwise
specified: 111; large cell carcinoma: 7; others: 39), chemo-
therapy alone was administered in 884 patients, concurrent
chemoradiotherapy in 245, sequential chemoradiotherapy in
43, and thoracic radiotherapy alone in 53 patients. To eval-
uate the incidence of TRD among the patients who received
chemotherapy, radiotherapy, or a combination of these mo-
dalities, we included the 43 patients who received sequential
chemoradiotherapy into both the chemotherapy-alone group
and the thoracic radiotherapy-alone group. Therefore, the
patients who received sequential chemoradiotherapy were
regarded as having been exposed to the risks of treatment
twice. The groups were therefore analyzed as chemotherapy
alone in 927 patients, concurrent chemotherapy in 245 pa-
tients, and thoracic radiotherapy alone in 96 patients. In these
groupings, the percentages of patients enrolled in clinical
trials were 62, 53, and 23%, respectively.
Cumulative Incidence and Causes of TRD
The cumulative incidence and causes of TRD are listed
in Table 2. Of the 1225 patients, a total of 23 (1.9%) TRDs
occurred. Chemotherapy-related deaths occurred in 7 of 927
(0.8%) patients, including 4 (0.4%) from drug-induced lung
injury (gefitinib, n  3 and CBDCA  gemcitabine, n  1),
2 (0.2%) from pneumonia (CBDCA  PTX, n  2), and 1
(0.1%) from unknown cause. The patient who died of un-
known cause experienced hemodynamic instability (shock) of
unknown etiology within 24 hours of ingestion of the first
dose of gefitinib (250 mg). No TRDs from sepsis occurred in
this series.
Concurrent chemoradiotherapy-related deaths occurred
in 12 of 245 (4.9%) patients, including 11 (4.5%) from
radiation pneumonitis and 1 (0.4%) from pneumonia during
the last planned cycle of CDDP  VNR. Radiotherapy-
TABLE 1. Patient Characteristics
Characteristics
Chemotherapy Alonea
(n  927)
Concurrent Chemoradiotherapy
(n  245)
Radiotherapy Alonea
(n  96)
Sex
Male 639 201 43
Female 288 44 53
Age
Median (range) 64 (27–86) 59 (18–77) 67 (35–81)
Performance status
0–1 871 245 88
2 140 0 8
3–4 16 0 0
Stage
III 297 235 71
IV 454 2 17
Postoperative recurrence 176 8 8
Histology
Non-small cell carcinoma 760 191 88
Small cell carcinoma 167 54 8
Coincidental lung disease
Pulmonary fibrosis 34 1 4
Pulmonary emphysema 69 30 1
Chemotherapy regimen
Platinum  taxane 368 21 —
Platinum  irinotecan 133 1 —
EGFR-TKI 125 0 —
Platinum  etoposide 95 54 —
Platinum  antimetabolite 85 0 —
Platinum  vinca alkaloid 37 168 —
Others 84 1 —
a Forty-three patients who received sequential chemotherapy followed by radiotherapy are included in the analysis of both the
chemotherapy-alone group and radiotherapy-alone group, as described in the text.
EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.
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related deaths occurred in 4 of 96 (4.2%) patients: all 4
(4.2%) patients died of radiation pneumonitis.
Risk Factors for TRD from Chemotherapy
Statistically significant factors identified by the univar-
iate analysis were a performance status of 2 to 4, hypoxia,
hypoalbuminemia, hyponatremia, out of clinical trials, and
treatment with epidermal growth factor receptor-tyrosine ki-
nase inhibitors (EGFR-TKIs) (Table 3). Although statistically
significant, the degrees of hyponatremia in the events were
neither clinically significant nor symptomatic for the range of
133 to 137 mEq/L. Pulmonary fibrosis and emphysema were
noted in 34 and 69 patients, respectively, among the 927
patients. None of these patients with lung disease died of
treatment in this study. Multivariate analysis was not per-
formed because the number of observed events was too small
(n  7).
Risk Factors for TRD from Concurrent
Chemoradiotherapy
None of the factors, except for pulmonary fibrosis, were
found to be statistically significant in the univariate analysis,
although a trend toward increase in the risk of TRD was
observed in patients of advanced age (70 years) and with
lower lobe as the primary tumor site (Table 4). Pulmonary
fibrosis appeared to be a statistically significant risk factor for
TRD; however, it was excluded from the multivariate anal-
ysis because of its limited incidence. Thus, we did not
perform multivariate analysis for chemoradiotherapy group,
and an analysis of the risk of TRD associated with thoracic
radiotherapy alone was not conducted because of the limited
number of cases.
DISCUSSION
We identified a total of 23 TRDs out of the 1225
patients (1.9%) enrolled in this study, which is lower than the
rate (2.7%) indicated in a previous report, particularly in
relation to the number of TRDs from infections, including
pneumonia and sepsis.1 The reason for the decrease in the
incidence of infection-related deaths is likely explained by
the infrequent use of triplet regimens when compared with
previous studies. Especially, mitomycin-C-containing regi-
mens are regarded as effective regimens in the treatment of
lung cancer; however, prolonged neutropenia has been ob-
served with these regimens. Ohe et al.1 reported that com-
bined mitomycin-C  vindesine  CDDP (MVP regimen)
therapy is a risk factor for chemotherapy-related TRD (toxic
deaths occurred in 9 of 301 patients; odds ratio [OR]  9.36,
95% confidence interval [CI]  1.29–68.0, p  0.027). In
this study, only 35 patients, the majority (89%) of whom were
enrolled in a clinical trial, received the MVP regimen. In the
past, however, the MVP regimen was widely used as part of
practice-based regimens (only 28% recorded under clinical
trials). In most cases, patients who were not eligible for
clinical trials ended up receiving the MVP regimen. Another
reason is the relatively frequent use of EGFR-TKI (in 13.5%
of the patients in this study) at present, which does not induce
myelosuppression. The reduction in the frequency of TRD
might also be explained by a progress in supportive care in
the treatments given for cancer treatment toxicities.
This study revealed that drug-induced lung injury was
the most frequent cause of TRD in the era of molecular-
targeted therapy. Three (75%) of four TRDs from drug-
induced lung injury were associated with gefitinib. The re-
TABLE 2. Treatment-Related Death and Its Cumulative Incidence
Characteristics
Chemotherapy Alonea
(n  927)
Concurrent Chemoradiotherapy
(n  245)
Radiotherapy Alonea
(n  96)
No. of treatment-related deaths 7 12 4
Cumulative incidence (%) 0.8 4.9 4.2
Sex
Male 5 11 4
Female 2 1 0
Age of patients who died of treatment (yr)
Median (range) 69 (46–77) 68 (50–77) 75 (65–77)
Causes
Treatment-induced lung injury 4 11 4
Infectious pneumonia 2 1 0
Unknown 1 0 0
Chemotherapy regimen
Platinum  taxane 2 2 —
EGFR-TKI 4 — —
Platinum  antimetabolite 1 — —
Platinum  etoposide 0 1 —
Platinum  vinca alkaloid 0 8 —
Others 0 1 —
a Forty-three patients who received sequential chemotherapy followed by radiotherapy are included in the analysis of both the chemotherapy-alone group and radiotherapy-alone
group, as described in the text.
EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.
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ported risk factors for interstitial lung disease in NSCLC
patients treated with gefitinib are male sex, history of smok-
ing, and underlying interstitial pneumonitis.11 In this study,
however, none of these factors were associated with TRD
from chemotherapy. Another TRD from drug-induced lung
injury occurred in a patient who received gemcitabine, but
this patient was also free from underlying pulmonary disease
or concomitant use of taxanes, which are reported to be risk
factors for gemcitabine-associated interstitial lung disease.12
For patients who receive concurrent chemoradiother-
apy, we would like to emphasize the previous finding that the
TABLE 3. Risk Factors for Treatment-Related Death from
Chemotherapy
Factors
No. of
Patients
Cumulative
Incidence (%)
Univariate
Analysis
OR (95% CI) p
Sex
Female 288 0.8 1
Male 639 0.7 1.13 (0.22–5.76) 0.89
Age
70 689 0.6 1
70 238 1.3 2.17 (0.51–9.30) 0.30
PS
0–1 870 0.5 1
2–4 57 5.2 11.4 (3.53–37.1) 0.001
Smoking history
No 271 0.4 1
Yes 656 0.9 2.49 (0.30–20.8) 0.40
PaO2 (Torr)
70 812 0.2 1
70 105 4.8 19.3 (6.06–61.7) 0.001
Hemoglobin (g/dl)
13.7 371 0.5 1
13.7 556 0.9 1.67 (0.33–8.39) 0.54
Albumin (g/dl)
3.7 663 0.3 1
3.7 264 1.9 6.28 (1.51–26.1) 0.012
AST (IU/L)
33 831 0.6 1
33 96 2.1 3.46 (0.75–16.0) 0.11
Na (mEq/L)
138 819 0.1 1
138 108 5.6 45.5 (13.4–154) 0.001
Clinical trial
No 355 1.7 1
Yes 572 0.2 0.10 (0.58–0.019) 0.001
Platinum  taxane
No 559 0.9 1
Yes 368 0.5 0.61 (0.12–3.14) 0.55
EGFR-TKIs
No 802 0.4 1
Yes 125 3.2 8.56 (2.48–29.5) 0.001
Platinum 
antimetabolite
No 842 0.7 1
Yes 85 1.1 1.66 (0.20–13.9) 0.64
Multivariate analysis was not performed because the number of observed events
was too small (n  7).
OR, odds ratio; CI, confidence interval; PS, performance status; AST, aspartate
transaminase; EGFR-TKIs, epidermal growth factor receptor-tyrosine kinase inhibitors.
TABLE 4. Risk Factors for Treatment-Related Death from
Concurrent Chemoradiotherapy
Factors
No. of
Patients
Cumulative
Incidence (%)
Univariate
Analysis
OR (95% CI) p
Sex
Female 44 2.3 1
Male 201 5.2 2.41 (0.35–16.6) 0.37
Age (yr)
70 221 4.1 1
70 24 12.5 3.07 (0.92–10.3) 0.069
PS
0 114 5.3 1
1 131 4.6 0.87 (0.29–2.62) 0.81
Smoking history
No 32 3.2 1
Yes 213 5.2 1.65 (0.23–11.9) 0.24
Fibrosis
No 244 4.5 1
Yes 1 100 22.2 (5.61–87.8) 0.001
Emphysema
No 215 4.7 1
Yes 30 6.7 1.43 (0.33–6.25) 0.63
Location of the tumor
Other lobes 189 3.7 1
Lower lobe 56 8.9 2.41 (0.82–7.13) 0.11
Histology
SCLC 54 1.9 1
NSCLC 191 5.8 3.11 (0.47–20.6) 0.24
Hemoglobin (g/dl)
13.7 146 4.1 1
13.7 99 6.1 1.48 (0.49–4.42) 0.48
Albumin (g/dl)
3.7 198 4.5 1
3.7 47 6.4 1.40 (0.40–4.99) 0.6
Na (mEq/L)
138 219 5.0 1
138 26 3.8 0.77 (0.11–5.60) 0.79
Clinical trial
No 114 5.3 1
Yes 131 4.6 0.87 (0.29–2.62) 0.81
Platinum  taxane
No 224 4.5 1
Yes 21 9.5 2.25 (0.46–11.0) 0.32
Platinum  vinca
alkaloid
No 77 5.2 1
Yes 168 4.8 0.91 (0.27–3.13) 0.88
Multivariate analysis was not performed because only fibrosis was significant in
univariate analysis.
OR, odds ratio; CI, confidence interval; PS, performance status; NSCLC, non-small
cell lung cancer.
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presence of evidence of pulmonary fibrosis on a plain chest
x-ray is an extremely strong risk factor for TRD (OR  166,
95% CI  8.79–3122, p  0.001).1 In this study, only one
patient with pulmonary fibrosis was identified, and pulmo-
nary fibrosis was not included in the multivariate analysis
because of the small number of patients with this factor,
because we generally exclude patients with evidence of
pulmonary fibrosis on the chest x-ray from consideration of
concurrent chemoradiotherapy. This study also suggested that
advanced age may be a risk factor for TRD. This is consistent
with the results of previous studies.1,13–15 The association
between advanced age and fatal radiation-induced lung injury
may be explained by the increased likelihood of these patients
developing comorbid lung disease, particularly among pa-
tients with a history of heavy tobacco exposure. A meta-
analysis of chemoradiotherapy using individual data from
1764 patients with locally advanced NSCLC showed that the
benefit of chemoradiotherapy was obtained in elderly patients
(71 years) as well as in younger patients. However, it might
be assumed that patients who are included in such trials are fit
patients with minimal comorbidities. In addition, despite the
increase in toxicity that accompanied chemoradiotherapy in
elderly patients, it seemed that they had disease control and
survival rates similar to those of younger patients.16
In conclusion, TRD occurred in a total of 1.9% of
patients and was caused in the majority of the cases by
treatment-related lung injury. This finding is in clear contrast
with previous reports which suggested that the principal
cause of TRD in lung cancer patients was septic shock.
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